IRulya Therapeutics Inc.
At a glance
Most recent filing on November 12, 2026 — a grant by Bonuccelli Catherine M. on Nov 9, 2026.
Since November 12, 2026: 0 open-market purchases and 0 open-market sales.
We hold 5 Form 4 lines, going back to November 12, 2026.
Insider trades
How to read a Form 4All 5 shown
- Bonuccelli Catherine M. Director17,000 sharesGrant
- Valentine James Elwood Director17,000 sharesGrant
- Wise John Drayton Director17,000 sharesGrant
- Militello John Chief Financial Officer80,000 sharesGrant
- PATTERSON LEONE D Director17,000 sharesGrant
CEO pay
What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.
Dr. Thye, fiscal year ended Dec 31, 2025: total $2,411,125, actually paid $3,944,367. First reported Apr 27, 2026.
Earlier fiscal years are part of the subscription.